Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma.
作者信息
Ollila Thomas A, Kurt Habibe, Waroich Jozal, Vatkevich John, Sturtevant Ashlee, Patel Nimesh R, Dubielecka Patrycja M, Treaba Diana O, Olszewski Adam J
机构信息
Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI.
The Warren Alpert Medical School of Brown University, Providence, RI; and.
出版信息
Blood. 2021 Feb 25;137(8):1120-1124. doi: 10.1182/blood.2020007236.
Abstract
摘要
相似文献
1
Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma.
Blood. 2021 Feb 25;137(8):1120-1124. doi: 10.1182/blood.2020007236.
2
Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma.
Blood. 2021 Mar 4;137(9):1256-1259. doi: 10.1182/blood.2020006338.
3
Branched clonal evolution: nodal follicular lymphoma and primary diffuse large B-cell lymphoma of the central nervous system.
Haematologica. 2019 Jul;104(7):e326-e329. doi: 10.3324/haematol.2018.214981. Epub 2019 Mar 19.
4
Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
Appl Immunohistochem Mol Morphol. 2020 Sep;28(8):e68-e71. doi: 10.1097/PAI.0000000000000655.
5
Gene expression profiles of central nervous system lymphoma predict poor survival in patients with diffuse large B-cell lymphoma.
Br J Haematol. 2014 Sep;166(5):794-7. doi: 10.1111/bjh.12902. Epub 2014 Apr 21.
6
Primary lymphoma of the central nervous system: just DLBCL or not?
Blood. 2009 Jan 1;113(1):7-10. doi: 10.1182/blood-2008-04-149005. Epub 2008 Sep 18.
7
MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
Ann Hematol. 2019 Jan;98(1):169-173. doi: 10.1007/s00277-018-3498-z. Epub 2018 Oct 11.
8
Clinicopathological study of gene rearrangement and microRNA expression of primary central nervous system diffuse large B-cell lymphomas.
Int J Clin Exp Pathol. 2013 Sep 15;6(10):2048-55. eCollection 2013.
9
Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.
Oncotarget. 2016 Nov 1;7(44):72033-72043. doi: 10.18632/oncotarget.12459.
10
Central nervous system lymphoma newly developed 12 years after remission of an ocular adnexal lymphoma.
Acta Haematol. 2013;130(4):247-50. doi: 10.1159/000350485. Epub 2013 Jul 11.
引用本文的文献
1
Comprehensive Genetic Analysis of Central Nervous System Involvement in Mycosis Fungoides: A Case Report.
EJHaem. 2025 Aug 1;6(4):e70118. doi: 10.1002/jha2.70118. eCollection 2025 Aug.
2
Reliable detection of CNS lymphoma-derived circulating tumor DNA in cerebrospinal fluid using multi-biomarker NGS profiling: insights from a real-world study.
Biomark Res. 2025 May 9;13(1):71. doi: 10.1186/s40364-025-00777-z.
3
Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B-cell lymphoma.
Br J Haematol. 2025 Jul;207(1):92-100. doi: 10.1111/bjh.20099. Epub 2025 Apr 22.
4
Central Nervous System Prophylaxis Approach in High-Risk Diffuse Large B-Cell Lymphoma Patients: A Retrospectively Collected, Single-Center Cohort Analysis.
Cancer Med. 2025 Apr;14(7):e70830. doi: 10.1002/cam4.70830.
5
Central nervous system involvement in Waldenström macroglobulinemia: a comparative population-based study of Bing-Neel syndrome and histological transformation.
Ann Hematol. 2025 Feb;104(2):1007-1014. doi: 10.1007/s00277-025-06194-4. Epub 2025 Jan 24.
6
The contemporary spectrum of radiotherapy for hematologic malignancies involving the central nervous system: From focal therapy to craniospinal.
Semin Radiat Oncol. 2025 Jan;35(1):126-137. doi: 10.1016/j.semradonc.2024.11.001.
7
Identification of genomic biomarkers of disease progression and survival in primary CNS lymphoma.
Blood Adv. 2025 Mar 11;9(5):1117-1131. doi: 10.1182/bloodadvances.2024014460.
8
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series.
Blood Adv. 2024 Oct 22;8(20):5355-5364. doi: 10.1182/bloodadvances.2024013791.
9
Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration.
Leukemia. 2024 Oct;38(10):2225-2234. doi: 10.1038/s41375-024-02371-y. Epub 2024 Aug 16.
10
Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma.
Leukemia. 2024 Jul;38(7):1541-1552. doi: 10.1038/s41375-024-02279-7. Epub 2024 May 15.
本文引用的文献
1
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.
Cancer Cell. 2020 Apr 13;37(4):551-568.e14. doi: 10.1016/j.ccell.2020.03.015.
2
Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles.
EBioMedicine. 2019 Oct;48:58-69. doi: 10.1016/j.ebiom.2019.09.034. Epub 2019 Oct 21.
3
Treatment strategies and risk of central nervous system recurrence in high-grade B-cell and Burkitt lymphoma.
Leuk Lymphoma. 2020 Jan;61(1):198-201. doi: 10.1080/10428194.2019.1654097. Epub 2019 Aug 21.
4
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
J Clin Oncol. 2019 Jul 20;37(21):1790-1799. doi: 10.1200/JCO.18.01994. Epub 2019 Apr 2.
5
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.
Blood. 2019 Feb 28;133(9):919-926. doi: 10.1182/blood-2018-07-862862. Epub 2019 Jan 7.
6
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.
J Clin Oncol. 2019 Jan 20;37(3):202-212. doi: 10.1200/JCO.18.01314. Epub 2018 Dec 3.
7
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
J Clin Oncol. 2019 Jan 20;37(3):190-201. doi: 10.1200/JCO.18.01583. Epub 2018 Dec 3.
8
Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Curr Treat Options Oncol. 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8.
9
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.
Nat Med. 2018 May;24(5):679-690. doi: 10.1038/s41591-018-0016-8. Epub 2018 Apr 30.
10
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
N Engl J Med. 2018 Apr 12;378(15):1396-1407. doi: 10.1056/NEJMoa1801445.
Zotero 插件